Shionogi & Co. (TYO:4507) posted a 90.5% year-over-year increase in profit attributable to owners of the parent to 97.7 billion yen for the fiscal first half ended June 30 from 39.4 billion yen.
The pharmaceutical company's revenue rose 48% to 163.3 billion yen from 99.8 billion yen in the year prior, according to a Tokyo Stock Exchange filing on Monday.
For the fiscal year ending March 31, 2027, the company forecasts an attributable profit of 210 billion yen and revenue of 700 billion yen.